Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-05-01

Study Completion Date

2036-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prognostic Value of Adipokine Levels of Patients With Chronic Heart Failure

NCT02812797

Chronic Heart Failure

COMPLETED

Optimized Cardioprotection Therapy in Obese Subjects With CAD

NCT04570527

Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) Obesity Adiposis; Heart

UNKNOWN

Assessment of Endothelial Function, Apolipoproteins and Adiponectin

NCT01300390

Cirrhosis

COMPLETED

Epicardial Adipose Tissue Volume and Attenuation in Acute Ischemic Stroke

NCT05631808

Ischemic Stroke

UNKNOWN

A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

NCT03307330

Obstructive Sleep Apnea of Adult

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction Cerebral Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

volunteer

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* available for 5 years of follow-up study

Exclusion Criteria

* Death caused other than cardiovascular and cerebralvascular diseases till the study ends
* Floating Population
* Pregnancy, lactation, or child bearing women
* Tumor
* Active hepatic disease or hepatic dysfunction, or AST/ALT \> 1.5UNL
* Severe renal dysfunction(Scr \> 3 mg/dl or 264μmol/L)
* Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes